CohBar, Inc.

Disclaimer : Sections of this page are auto-generated by Artificial Intelligence and shall not be understood as Investment Advice
This page was updated : 2023-05-31 04:05:38 UTC

Law firm Kahn Swick & Foti is investigating the merger of CohBar, Inc. (CWBR) and has issued an investor alert.

Based on these articles
  1. COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR
Business Overview

As an investment analyst, CohBar, Inc.'s business model can be described as a biotechnology company that focuses on the development of innovative peptide-based therapeutics for the treatment of various diseases associated with aging. The company's primary focus is on developing drugs that target mitochondrial dysfunction, which is a key driver of aging-related diseases such as diabetes, cardiovascular disease, and neurodegenerative disorders. CohBar's business model is based on a platform technology that allows the company to discover and ...

Yahoo - Business Overview

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

Risk Rating (Yahoo)


ESG Score (Yahoo)


Market Cap (USD)

8 M

AI Rank (finclout)


Flags & Key Risks
Negative profit margins Negative Return on Equity Clinical stage company Negative Debt Trend No Revenue Pre-market negative on higher volumes
  • Market risk - CohBar, Inc. operates in a highly competitive and rapidly changing market, which may impact its ability to generate revenue and profits.
  • Clinical trial risk - CohBar, Inc. is heavily reliant on the success of its clinical trials, which may not yield positive results and could lead to significant financial losses.
  • Regulatory risk - CohBar, Inc. is subject to regulatory approval for its products, which may be delayed or denied, impacting its ability to bring products to market.
  • Intellectual property risk - CohBar, Inc. relies on its intellectual property to protect its products and technologies, but there is a risk that its patents may be challenged or invalidated.
  • Financial risk - CohBar, Inc. has a history of losses and may require additional funding to continue operations, which could dilute the value of existing shares.

SWOT Analysis


CohBar has a strong pipeline of peptide-based drugs that have potential in treating various diseases.  


As a biotech company, CohBar is heavily reliant on the success of its drug development programs, which can be unpredictable and risky.                                


The aging population and increasing prevalence of age-related diseases provide a growing market for CohBar's drugs. Additionally, partnerships with larger pharmaceutical companies could provide additional resources and expertise for drug development.


Competition from other biotech and pharmaceutical companies in the development of peptide-based drugs, as well as regulatory hurdles and changes in healthcare policies, could pose threats to CohBar's success.

Thesis for CohBar, Inc.


CohBar, Inc. has a strong pipeline of potential drug candidates that target age-related diseases such as cancer, Alzheimer's, and cardiovascular disease. The company's innovative approach to developing therapeutics that target mitochondrial dysfunction ha ...


CohBar, Inc. is a biotechnology company focused on developing therapeutics that target mitochondrial dysfunction. While the company's pipeline of potential drug candidates is promising, there is still a significant amount of research and development ...


CohBar, Inc. is a preclinical biotechnology company with no products on the market and a limited track record of success. The company's focus on developing therapeutics that target mitochondrial dysfunction is unproven, and there is no guarantee that any ...

News Coverage

No articles found for
7 days ago @InvestorsLive
@Chris87945700 In due time, what if they have a plan to do reverse $CWBR yesterday in AHs as they walk down and trap?
#CWBR #investorslive #trap #cwbr #walk #reverse
8 days ago @James_Foresight
#CWBR #bsyvpzbhpsjames_foresight #cwbr #CWBR
8 days ago @Bullish_Trades
$CWBR Sub 5M floats continue to be the main runners this month
#CWBR #floats #runners #cwbr #main #continue
8 days ago @InvestorsLive
$CWBR just another day in small cap fukary land lol So glad this came off my radar 10:54:46 am InvestorsLive CWB…
#CWBR #radar #fukary #land #investorslive #cwbr
8 days ago @Mitch___Picks
Good morning - Today's watchlist going into the open: $SHPH $CWBR $HTCR $MCLD $HEPA
#CWBR #hepamitch___picks #mcld #shph #htcr #cwbr
8 days ago @Mini_Tradez
beautiful start to the morning $CWBR 3.80--->4.66 $SHPH
#CWBR #shph #cwbr #beautiful #start #morning
8 days ago @StockSwingAlert
$CWBR nhod $3.75 to $5 complete ? This is the golden rule. It’s how I know we live in a simulator ???…
#CWBR #simulator #nhod #golden #cwbr #complete
8 days ago @Mini_Tradez
5 cents off of my level $CWBR NO FOMO all good
#CWBR #fomo #cents #cwbr #level #good
8 days ago @StockSwingAlert
$CWBR up 187% ??? Called before the halt reopened - Bang bang! ? Best in the business 24/7 365. ?
#CWBR #bang #halt #reopened #cwbr #called
8 days ago @InvestorsLive
$CWBR oh they meant business - sick rip glad that was off radar lol
#CWBR #sick #radar #glad #meant #cwbr
No research found for
No filings found for
Offcanvas top
Offcanvas left






Offcanvas bottom
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.